Lytix Biopharma Overview

  • Founded
  • 2003
Founded
  • Status
  • Private
  • Employees
  • 14
Employees
  • Latest Deal Type
  • IPO
  • (Cancelled)
  • Latest Deal Amount
  • $33.9M
Latest Deal Amount
  • Investors
  • 11

Lytix Biopharma General Information

Description

Developer of drugs designed to provide the treatment of antibiotic-resistant infections and cancer. The company's drug conducts research in the fields of synthetic peptide therapeutics and the therapies are focused on destroying bacteria and cancer cells, enabling patients to achieve an active immune system in the process.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • P.O. Box 6447
  • 9294 Tromsø
  • Norway
+47 77 00 00 00

Lytix Biopharma Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Lytix Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. IPO 20-Apr-2018 $33.9M Cancelled Clinical Trials - Phase 1
12. Later Stage VC 22-Aug-2017 000.00 0000 0000 Completed Clinical Trials - Phase 1
11. Grant 30-Jan-2017 00.000 000.00 Completed Clinical Trials - Phase 1
10. Accelerator/Incubator 11-Feb-2016 000.00 Completed Clinical Trials - Phase 1
9. Later Stage VC 15-Dec-2015 00.00 000.00 Completed Clinical Trials - Phase 1
8. Later Stage VC 01-Jan-2015 00.000 000.00 Completed Clinical Trials - Phase 1
7. Later Stage VC 22-Dec-2014 00.000 000.00 Completed Clinical Trials - Phase 1
6. Grant 07-Nov-2013 00.00 000.00 Completed Clinical Trials - Phase 1
5. Later Stage VC 01-Jan-2013 $15.1M $50.2M Completed Clinical Trials - Phase 1
4. Later Stage VC 01-Jan-2011 $8.38M $35.1M Completed Clinical Trials - Phase 1
To view Lytix Biopharma’s complete valuation and funding history, request access »

Lytix Biopharma Executive Team (14)

Name Title Board Seat Contact Info
Øystein Rekdal Ph.D Co-Founder & Chief Executive Officer
Gjest Breistein Chief Financial Officer
Baldur Sveinbjørnsson Ph.D Chief Scientific Officer
John Svendsen Ph.D Director Discovery Research
Hamina Patel Chief Medical Officer
You’re viewing 5 of 14 executive team members. Get the full list »

Lytix Biopharma Board Members (10)

Name Representing Role Since
Gert Munthe Self Board Member 000 0000
Per Sørensen Lytix Biopharma Board Member 000 0000
You’re viewing 2 of 10 board members. Get the full list »

Lytix Biopharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lytix Biopharma Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Norwegian Cancer Society Other Minority 000 0000 000000 0
Norwegian Research Council Other 000 0000 000000 0
Oslo Cancer Cluster Incubator Accelerator/Incubator Minority 000 0000 000000 0
Care Holding Other Minority 000 0000 000000 0
Hopen Invest Other Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »